Moderna 2022 Priorities and Capital Allocation

Data from the UK show that boosters against the wild-type virus protect against Omicron variant BA.2 but waning continues Vaccine effectiveness against symptomatic disease after 2 doses or a booster dose across vaccine types 100 80 50 Vaccine effectiveness (%) 40 40 ------------ -O-i 20 HO¬ |---- <2 2-24 25+ <1 1 2-4 Dose 2 0 5-9 10-14 15+ Booster Primary series: BNT162b2, ChAdOx1, mRNA-1273 Booster dose: BNT162b2 or mRNA-1273 Slide 10 BA.2 Time since Vaccine (weeks) UK Health Security Agency, COVID-19 vaccine surveillance report, Week 17 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1072064/Vaccine-surveillance-report-week-17.pdf OBA.1 moderna

View entire presentation